Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01009086
Registration number
NCT01009086
Ethics application status
Date submitted
5/11/2009
Date registered
6/11/2009
Date last updated
3/03/2015
Titles & IDs
Public title
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
Query!
Scientific title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Aanti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
Query!
Secondary ID [1]
0
0
CNTO1275PSA3001
Query!
Secondary ID [2]
0
0
CR016315
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Arthritis, Psoriatic
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Ustekinumab 45 mg
Treatment: Drugs - Ustekinumab 90 mg
Experimental: Placebo - Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
Experimental: Ustekinumab 45 mg - Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
Experimental: Ustekinumab 90 mg - Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
Treatment: Drugs: Placebo
SC injections
Treatment: Drugs: Ustekinumab 45 mg
SC injections
Treatment: Drugs: Ustekinumab 90 mg
SC injections
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24.
Query!
Assessment method [1]
0
0
An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 20 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 centimeters [cm]) 4) Participant's assessment of physical function as measured by the "Disability Index of the Health Assessment Questionnaire" (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.
Query!
Timepoint [1]
0
0
Week 24
Query!
Secondary outcome [1]
0
0
Change From Baseline to Week 24 in the Disability Index Score as Measured With the "Disability Index of the Health Assessment Questionnaire" (HAQ-DI)
Query!
Assessment method [1]
0
0
The HAQ-DI is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). The average score across the functional areas yields an overall HAQ-DI score which ranges from 0 (no disability) to 3 (completely disabled). In psoriatic arthritis, a decrease in score of 0.30 indicates clinically meaningful improvement.
Query!
Timepoint [1]
0
0
Day 1 (Baseline) and Week 24
Query!
Secondary outcome [2]
0
0
Percentage of Participants (With >= 3% Baseline Body Surface Area (BSA) Psoriatic Involvement) Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24
Query!
Assessment method [2]
0
0
The PASI is a physician-administered assessment tool used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). A PASI 75 response is defined as greater than or equal to 75 percent improvement in PASI score from baseline.
Query!
Timepoint [2]
0
0
Week 24
Query!
Secondary outcome [3]
0
0
Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Week 24
Query!
Assessment method [3]
0
0
An ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 50 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 cm) 4)Participant's assessment of physical function as measured by the "Disability Index of the Health Assessment Questionnaire" (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.
Query!
Timepoint [3]
0
0
Week 24
Query!
Secondary outcome [4]
0
0
Percentage of Participants With American College of Rheumatology (ACR) 70 Response at Week 24
Query!
Assessment method [4]
0
0
An ACR 70 response is defined as a greater than or equal to 70 percent improvement from baseline in swollen (66 joints) and tender (68 joints) joint counts and greater than or equal to 70 percent improvement in 3 of the following 5 assessments: 1) Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm), 2) Participant's global assessment of disease activity by VAS (0-10 cm), 3) Physician's global assessment of disease activity by VAS (0-10 cm) 4) Participant's assessment of physical function as measured by the "Disability Index of the Health Assessment Questionnaire" (HAQ-DI) (score of 0-3 in 8 functional areas) and 5) C reactive protein.
Query!
Timepoint [4]
0
0
Week 24
Query!
Secondary outcome [5]
0
0
Change From Baseline to Week 24 in Total Modified Van Der Heijde-Sharp (vdH-S) Score for the Combined Radiographic Data From Studies CNTO1275PSA3001 and CNTO1275PSA3002
Query!
Assessment method [5]
0
0
The modified vdH-S score is a radiographic evaluation of hand and feet erosions and joint space narrowing (JSN) for 20 joints per hand and 6 joints per foot with a total score ranging from 0 (best) to 528 (worst = worst possible erosion score of 320 + worst possible JSN score of 208). Higher score and positive score changes indicate more radiographic damage and radiographic progression, respectively. As per protocol, analysis for this outcome measure used pooled data from 2 studies (CNTO1275PSA3001 and PSA3002) because initial power assumptions showed that 900 participants would be required to evaluate impact of ustekinumab on structural damage (SD) progression. The 2 studies, (which had similar study designs and dosing regimens with difference to prior exposure to anti-tumor necrosis factor alpha (TNFa) therapies), were intended to independently measure efficacy in terms of signs, symptoms and physical function, while effects on SD progression is provided from an integrated analysis.
Query!
Timepoint [5]
0
0
Day 1 (Baseline) and Week 24
Query!
Eligibility
Key inclusion criteria
- Have had a documented diagnosis of psoriatic arthritis (PsA) at least 6 months
- Have a diagnosis of active PsA at the time of entry into the study
- If the participant is using methotrexate they should have started treatment at a dose
not to exceed 25 milligram per week at least 3 months prior to the beginning of the
study and should have no serious toxic side effects attributable to methotrexate.
Methotrexate route of administration and doses should be stable for at least 4 weeks
prior to the first administration of study agent. If currently not using methotrexate,
must have not received methotrexate for at least 4 weeks prior to the first
administration of the study agent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Have other inflammatory diseases, including but not limited to rheumatoid arthritis,
ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease
- Have used any therapeutic agent targeted at reducing interleukin (IL)-12 or IL-23,
including but not limited to ustekinumab and briakinumab (ABT-874)
- Have used any biologic agents that are targeted for reducing tumor necrosis
factor-alpha, including but not limited to infliximab, etanercept, adalimumab, and
golimumab
- Have a medical history of latent or active granulomatous infection
- Have any known malignancy or have a history of malignancy (with the exception of basal
cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in
situ that has been treated with no evidence of recurrence, or squamous cell carcinoma
of the skin that has been treated with no evidence of recurrence within 5 years of the
beginning of the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/05/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
615
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Camperdown
Query!
Recruitment hospital [2]
0
0
- Heidelberg
Query!
Recruitment hospital [3]
0
0
- Maroochydore
Query!
Recruitment hospital [4]
0
0
- Melbourne
Query!
Recruitment hospital [5]
0
0
- Perth
Query!
Recruitment hospital [6]
0
0
- Woodville
Query!
Recruitment postcode(s) [1]
0
0
- Camperdown
Query!
Recruitment postcode(s) [2]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [3]
0
0
- Maroochydore
Query!
Recruitment postcode(s) [4]
0
0
- Melbourne
Query!
Recruitment postcode(s) [5]
0
0
- Perth
Query!
Recruitment postcode(s) [6]
0
0
- Woodville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Minnesota
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Nebraska
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Jersey
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oklahoma
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oregon
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Pennsylvania
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Tennessee
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Washington
Query!
Country [20]
0
0
Austria
Query!
State/province [20]
0
0
Graz
Query!
Country [21]
0
0
Austria
Query!
State/province [21]
0
0
Innsbruck
Query!
Country [22]
0
0
Austria
Query!
State/province [22]
0
0
Wien N/A
Query!
Country [23]
0
0
Austria
Query!
State/province [23]
0
0
Wien
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Alberta
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
British Columbia
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
New Brunswick
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Newfoundland and Labrador
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Nova Scotia
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Ontario
Query!
Country [30]
0
0
Canada
Query!
State/province [30]
0
0
Quebec
Query!
Country [31]
0
0
Finland
Query!
State/province [31]
0
0
Helsinki
Query!
Country [32]
0
0
Finland
Query!
State/province [32]
0
0
Hyvinkää
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Berlin
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Frankfurt
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Hamburg
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Herne
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Kiel
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Mahlow
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Mainz
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Regensburg
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Tübingen
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Budapest N/A
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Budapest
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Debrecen
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Kecskemét
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Szeged
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Szolnok
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Veszprém
Query!
Country [49]
0
0
Latvia
Query!
State/province [49]
0
0
Riga
Query!
Country [50]
0
0
Lithuania
Query!
State/province [50]
0
0
Alytus
Query!
Country [51]
0
0
Lithuania
Query!
State/province [51]
0
0
Kaunas
Query!
Country [52]
0
0
Lithuania
Query!
State/province [52]
0
0
Klaipeda
Query!
Country [53]
0
0
Lithuania
Query!
State/province [53]
0
0
Siauliai
Query!
Country [54]
0
0
New Zealand
Query!
State/province [54]
0
0
Auckland
Query!
Country [55]
0
0
New Zealand
Query!
State/province [55]
0
0
Christchurch
Query!
Country [56]
0
0
New Zealand
Query!
State/province [56]
0
0
Rotorua
Query!
Country [57]
0
0
New Zealand
Query!
State/province [57]
0
0
Wellington
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Bialystok
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Bydgoszcz
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Elblag
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Lublin
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Torun
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Warszawa
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Ekaterinburg
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Korolev
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Moscow
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Novosibirsk
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
Rostov-On-Don
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
Saint Petersburg
Query!
Country [70]
0
0
Russian Federation
Query!
State/province [70]
0
0
Saratov
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Barcelona
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Oviedo
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Santiago De Compostela
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Sevilla
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Cannock
Query!
Country [76]
0
0
United Kingdom
Query!
State/province [76]
0
0
Glasgow
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
London
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Salford
Query!
Country [79]
0
0
United Kingdom
Query!
State/province [79]
0
0
Wigan
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the effectiveness (improvement of signs and
symptoms) and safety of ustekinumab in participants with active psoriatic arthritis.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01009086
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01009086
Download to PDF